Astellas signs option deal for DAX-044 worth up to $1.34 billion
Astellas Pharma has secured an exclusive option and license for Audax's DAX-044, with total potential payments of up to $1.34 billion excluding royalties.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Astellas Pharma has entered an exclusive option and license agreement for DAX-044 from Audax, according to TradingView, which cited a press release distributed by PR Newswire. Total potential payments reach up to $1.34 billion, excluding royalties.
Audax will receive up to $285 million in upfront and option payments and will fund development until the Phase 1 start, expected in 2027. Astellas gets a global option, while milestones of up to $1.05 billion depend on development and commercial success. Royalties are tiered at double-digit percentages.
why it matters
The deal is an early-stage expansion of the pipeline in immuno-oncology. For Astellas, it represents potential future cash outflows that depend on whether it exercises the option. Key events to watch are the Phase 1 start, first data, and Astellas's decision after required clearances.
market impact
Astellas: a large oncology bet with deferred payments, with a moderate effect on the shares
tags
instruments
sources
- Astellas Pharma Inc. Signs Option Deal for DAX-044 Worth Up To $1.34B — TradingView, 27 October 2026 at 23:30 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗